Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
GSK Rebuts Teva’s ‘Doomsday Scenario’ On Skinny-Label Generics
Originator Urges US Supreme Court To Reject Review Of Indication Carve-Out Lawsuit
Sep 08 2022
•
By
Dave Wallace
Teva’s “doomsday scenario” falls apart under scrutiny, GSK claims • Source: Shutterstock
More from Legal & IP
More from Generics Bulletin